For research use only
| Cat No. | ABC-SC0212 |
| Product Type | Human iPSCs |
| Cell Type | Induced Pluripotent Stem Cell |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Fibroblast |
| Disease | Amyotrophic Lateral Sclerosis |
| Storage | Liquid Nitrogen |
HighQC™ Human ALS iPSC from fibroblasts express pluripotency markers,non-tumorigenic, suitable for ALS modeling,neural differentiation,and drug screening.
HighQC™ Human iPSC from Fibroblast–Amyotrophic Lateral Sclerosis (ALS) is a patient-derived induced pluripotent stem cell (iPSC) line reprogrammed from dermal fibroblasts of individuals with ALS. These cells exhibit typical iPSC morphology with high nucleus-to-cytoplasm ratio, prominent nucleoli, and tight colony formation. Reprogrammed using non-integrating methods, they express core pluripotency markers such as OCT4, SOX2, and NANOG. Karyotype analysis indicates a normal diploid karyotype. They can be differentiated into neural and glial lineages to replicate disease-relevant phenotypes in vitro, making them suitable for investigating disease mechanisms and neurodegeneration.
| Product Code | HighQC™ Human IPSC From Fibroblast-Amyotrophic Lateral Sclerosis, Human iPSC-Fibroblast-ALS, hIPSC-F-ALS, Human Fibroblast Derived iPSC ALS |
| Species | Human |
| Cat.No | ABC-SC0212 |
| Product Category | Stem Cells |
| Size/Quantity | 1 vial |
| Cell Type | Induced Pluripotent Stem Cell |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Fibroblast |
| Disease | Amyotrophic Lateral Sclerosis |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human iPSCs |
HighQC™ Human iPSC from Fibroblast–Amyotrophic Lateral Sclerosis (ALS) serve as a powerful tool for modeling amyotrophic lateral sclerosis in vitro. They can be differentiated into motor neurons, astrocytes, or oligodendrocytes to study cell-type-specific pathology, gene expression, and neurotoxicity. These cells are also valuable for drug screening, gene-editing validation, and personalized therapeutic development. ALS patient-derived iPSCs enable exploration of disease progression, neuroinflammation, and cellular stress mechanisms within a patient-specific genetic context.
When you publish your research, please cite our product as "AcceGen Biotech Cat.# XXX-0000". In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).